Training in cortically-blind fields confers patient-specific benefit against retinal thinning after occipital stroke

Berkeley K. Fahrenthold; Matthew R. Cavanaugh; Madhura Tamhankar; Byron L. Lam; Steven E. Feldon; Brent A. Johnson; Krystel R. Huxlin

doi:10.1101/2023.12.19.23298260

Abstract

Purpose Damage to the adult primary visual cortex (V1) causes vision loss in the contralateral hemifield, initiating a process of trans-synaptic retrograde degeneration (TRD). Here, we examined retinal correlates of TRD using a new metric to account for global changes in inner retinal thickness, and asked if perceptual training in the intact or blind field impacts its progression.

Methods We performed a meta-analysis of optical coherence tomography (OCT) data in 48 participants with unilateral V1 stroke and homonymous visual defects, who completed clinical trial NCT03350919. After measuring the thickness of the macular ganglion cell and inner plexiform layers (GCL-IPL), and the peripapillary retinal nerve fiber layer (RNFL), we computed individual laterality indices (LI) at baseline and after ∼6 months of daily motion discrimination training in the intact- or blind-field. Increasingly positive LI denoted greater layer thinning in retinal regions affected versus unaffected by the cortical damage.

Results Pre-training, the affected GCL-IPL and RNFL were thinner than their unaffected counterparts, generating LI values positively correlated with time since stroke. Participants trained in their intact-field exhibited increased LI_GCL-IPL. Those trained in their blind-field had no significant change in LI_GCL-IPL. LI_RNFL did not change in either group.

Conclusions Relative shrinkage of the affected versus unaffected macular GCL-IPL can be reliably measured at an individual level and increases with time post-V1 stroke. Relative thinning progressed during intact-field training, but appeared to be halted by training within the blind field, suggesting a potentially neuroprotective effect of this simple behavioral intervention.

Competing Interest Statement

Krystel R. Huxlin, inventor on US Patent No. 7,549,743

Clinical Trial

NCT03350919

Funding Statement

This work was supported by NIH funding (R01 EY027314 to KRH, as well as T32 EY007125 and P30 EY001319 to the Center for Visual Science), and by an Unrestricted Grant from the Research to Prevent Blindness (RPB) Foundation to the Flaum Eye Institute. The HIS clinical trial was funded by a Center of Emerging and Innovative Science for Empire State Development (project no. 1730C004), a Center of Excellence (project no. 1689bC2) and EnVision Solutions LLC. The sponsors and funding organizations had no role in the design or conduct of this research.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All procedures conducted as part of the clinical trial were approved by the Western Institutional Review board (WIRB#1181904).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

Funding Information: This work was supported by NIH funding (R01 EY027314 to KRH, as well as T32 EY007125 and P30 EY001319 to the Center for Visual Science), and by an Unrestricted Grant from the Research to Prevent Blindness (RPB) Foundation to the Flaum Eye Institute. The HIS clinical trial was funded by a Center of Emerging and Innovative Science for Empire State Development (project no. 1730C004), a Center of Excellence (project no. 1689bC2) and EnVision Solutions LLC. The sponsors and funding organizations had no role in the design or conduct of this research.
Commercial Relationships Disclosures: KRH is an inventor on US Patent No. 7,549,743. The remaining authors have no competing interests.

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Non-standard Abbreviations and Acronyms

CB: Cortical Blindness
OCT: Optical Coherence Tomography
LI: Laterality Index
dLGN: dorsal lateral geniculate nucleus
GCL-IPL: Ganglion Cell Layer-Inner Plexiform Layer
RGC: Retinal Ganglion Cell
HIS: Hemianopia Intervention Study
HVF: Humphrey Visual Field
OU: Oculus Uterque (both eyes)
OS: Oculus Sinister (left eye)
OD: Oculus Dextrus (right eye)
SEM: Standard Error Mean
PMD: Perimetric Mean Deviation
ST_BF: Mean Sensitivity of Blind Field
TRD: Trans-synaptic Retrograde Degeneration

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.